Biothrax clinical trials
Also written BioThrax and Anthrax Vaccine Adsorbed.
How each study uses Biothrax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 12 Nov 1998 · Biothrax · BLA 103821 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Emergent BioSolutions (2) · Centers for Disease Control and Prevention (1) · Biomedical Advanced Research and Development Authority (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Biothrax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Ciprofloxacin BioThrax Co-Administration StudyCompletedPhase 2Emergent BioSolutionsNCT01753115Written as BioThrax
- Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route ChangeCompletedPhase 4Centers for Disease Control and PreventionNCT00119067Written as Anthrax Vaccine Adsorbed
- Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCompletedPhase 3Emergent BioSolutionsNCT01491607Written as BioThrax
- BARDA Securing Anthrax Immunity For the ElderlyCompletedPhase 2Biomedical Advanced Research and Development AuthorityNCT03518125Written as BioThrax
- Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA ScheduleCompletedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT01641991Written as BioThrax®
As the comparator · 4 — what is tested is compared with Biothrax
- VELOCITY: An Anthrax Vaccine Clinical StudyCompletedPhase 3Emergent BioSolutionsNCT03877926Written as BioThrax
- NasoShield Study of Safety and ImmunogenicityCompletedPhase 1Altimmune, Inc.NCT03352466Written as BioThrax
- Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCompletedPhase 1Emergent BioSolutionsNCT01263691Written as BioThrax
- A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCompletedPhase 2Emergent BioSolutionsNCT01770743Written as BioThrax
Codes
What other systems call Biothrax · ClinicalTrials.gg INT004713
- RxNorm 1368371One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 1368371 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.